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Abstract Intensive treatment for newborns with trisomy
13 is controversial because of their lethal prognosis. We
report the better life prognosis of patients with trisomy 13
who received intensive treatment. At our hospital, we
provided an intensive management to such patients
including resuscitation and surgical procedures as required.
Herein, we present the results of a retrospective study
(1989–2010) of 16 trisomy 13 cases who received an
intensive treatment. None was diagnosed to have trisomy
13 before birth; 9 were delivered by C-section and oxygen
was administered to all patients during postpartum resus-
citation. Mechanical ventilation was used in 9 patients after
tracheal intubation and tracheotomy was performed in
2 patients when withdrawing of extubation was difﬁcult.
Regarding prognosis, 9 patients died, 3 were referred to
another hospital, and 4 were discharged from the hospital.
Four and 7 patients died within 7 and 30 days after birth,
respectively. Nine patients survived for [1 month, 7 for
[180 days, and 5 for [3 years. Median survival for 16
patients was 733 days. The patients who received intensive
treatments survived longer compared to the previous data.
This study provides useful information concerning genetic
counseling, especially from an ethical point of view,
before providing intensive management to newborns with
trisomy 13.
Keywords Trisomy 13  Prognosis  Intensive treatment 
Survival  Natural history
Introduction
Trisomy 13, ﬁrst reported by Patau et al. [1], is the third
common trisomy in live born infants. It is clinically asso-
ciated with various anomalies, found in 80 %, of cardiac
and circulatory systems, such as mainly ventricular septal
defect, patent ductus arteriosus, auricular septal defect and
60–80 % with cleft lip and/or palate of mouth, and 50 % or
more with the following: central nervous system with
holoprosencephaly, hearing system with apparent deafness,
cranium with microcephaly with sloping forehead, eyes
with microphthalmia and colobomata of iris, retinal dys-
plasia, abnormal auricle helices, skin with capillary hem-
angioma of forehead, distal palmar axial triadii, simian
crease, hypoconvex narrow ﬁngernails, ﬂexion of ﬁngers
with or without overlapping and camptodactyly, polyda-
cyly of hand, skeletal of thin posterior ribs and hypoplasia
of pelvis, males with cryptorchidism/abnormal scrotum and
females with bicornuate uterus and another malformation
accompanied by severe psychomotor disorder [2, 3]. The
prevalence studies from Denmark and United Kingdom
reported birth prevalence in live born of trisomy 13 as *1
in 20,000 to 1 in 29,000 [4, 5]. The Hawaiian study
reported prevalence at birth of trisomy 13 as 1 in 12,048 in
live born infants [6]. Jones described that the incidence was
*1 in 5,000 births [3]. Generally, natural prevalence of
delivery at birth of trisomy 13 is between 1 in 5,000 and
1 in 29,000, which is the third most common autosomal
trisomy in newborns following trisomy 21 and trisomy 18.
The approach to the management policy of a third-tri-
mester fetus and infant with trisomy 13 and 18 is quite
complicated, and the existing literature is controversial.
The principal reason for the complexity surrounding deci-
sion making in the care of infants with trisomy 13 relates to
high neonatal and infant mortality in both conditions [7, 8].
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known to have trisomy 13 appears to be the trend in
Denmark as shown by obstetrics literature. There was
strong consensus among physicians working in perinatal
medicine toward abortion for social reasons or because of
abnormal prenatal diagnostic results that abortion is
acceptable until week 21 in the case of trisomy 13 [9].
Moreover, there tends to be extremely negative information
about survival of trisomy 13. It is important to acknowl-
edge that the prognosis is lethal. Approximately, 50 % of
infants with trisomy 13 will live longer than a week and
5–10 % of infants will live past 1 year [7, 8]. Tradition, as
reﬂected in the pediatric literature, also indicates a nonin-
tervention approach in the newborn management of tri-
somy 13. Bos et al. [10] summarized these issues, arguing
that early diagnosis was very important so that surgery
could be withheld. The important issues that emerge in the
counseling and management of newborn infants with tri-
somy 13 are high infant mortality. Survivors have severe
mental retardation, often seizures, and fail to thrive. So that
surgical or orthopedic corrective procedures should be
withheld in early infancy to await the outcome of the ﬁrst
few months [3].
In Japan, the policies for the treatment of chromosomal
anomalies including trisomy 13 and 18 with poor long-term
prognoses are determined based on either of two contro-
versial concepts: (i) the provision of thorough love and care
while avoiding excessive intensive treatment; or (ii) the
provision of active intensive treatment including resusci-
tation and surgery according to the clinical conditions of an
infant and in accordance with the wishes of the infant’s
parents [11, 12]. The most important problems in this
argument were that there was no evidence about the
improvement of prognosis of trisomy 13 treated at the
Neonatal Intensive Care Unit (NICU) of Dokkyo Medical
University Hospital. In the same context, Kosho et al. [11,
13] investigated the prognosis of intensive treatments in 24
Japanese patients with trisomy 18 at NICU. This report
argued better prognosis of trisomy 18 through treatment at
NICU based on improved survival period, and the data
provide helpful guidelines for clinicians by offering the
best information on treatment options for families of
patients with trisomy 18. However, there is still a lack of
precise data concerning the clinical details and prognosis
regarding intensive treatments of patient with trisomy13.
The NICU at the Dokkyo Medical University Hospital
provides the intensive treatments including resuscitation of
intratracheal intubation, respiratory support, and some kind
of surgery for trisomy 13 and 18, if informed consent is
obtained from the family after counseling. At NICU, the
ﬁve tentative treatment policies for trisomy 13 and 18 with
poor long-term prognoses of survival are as follows: (1)
The treatment policy is determined without relation with
trisomy 13 and 18, and is determined after the pathology,
treatment options and risks involved have been explained
to the parents; (2) The actual initial treatment with resus-
citation and medical therapy after delivery are provided to
neonates who have ordinary cases, and surgical treatment is
also not limited; (3) With respect to surgical treatment and
resuscitation, even in case of long-term survival; (4) Psy-
chological care for family is regularly provided by clinical
psychotherapists; and (5) Management at home is actively
discussed if the family wishes for it.
In this study, in order to determine the survival period of
trisomy 13 patients who received intensive treatment,
we retrospectively analyzed the detailed clinical data of
16 patients with trisomy 13, admitted to NICU at the
Dokkyo Medical University Hospital from 1989 to 2010.
Patients and Methods
This study comprised 6,230 newborn infants who were
hospitalized at the neonatal care unit of Dokkyo University
Hospital, Japan during the period of 22 years from 1989 to
2010. Newborn infants presenting with external malfor-
mations or organ malformations that were observed during
the clinical examinations underwent chromosomal
analysis, and 183 patients (2.94 %) were diagnosed with
chromosomal anomalies. Of these, 138 patients (2.22 %)
were diagnosed with numerical autosomal aberration. A
breakdown of these patients of numerical autosomal aber-
ration shows trisomy 21 in 83 patients (1.33 %), trisomy 18
in 39 patients (0.63 %), and trisomy 13 in 16 patients
(0.26 %). Other chromosomal abnormalities were 45
patients (0.72 %) including 2 patients with trisomy 8
mosaic and 2 patients with 4p-syndrome and others. In this
study, we retrospectively investigated the NICU medical
records at our hospital regarding the clinical details of 16
patients with trisomy 13 who received intensive treatment.
Results
Family History, Ages of the Parents, History
of Pregnancy, and Delivery (Table 1)
None of the 16 patients with trisomy 13 had chromosomal
abnormalities in their family histories. The age of the
mothers ranged from 20 to 42 years (average: 32.9
years) including mothers who were over 35-years-old for
7patientsandover40-years-oldfor2patients.Theageofthe
fathers ranged from 22 to 47 years (average: 33.8 years)
including fathers who were over 35-years-old for 7 patients
andover40-years-oldfor3patients.Regardingthehistoryof
previous delivery,5patientshadparousmothers. Intermsof
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123gender, there were 10 males and 6 females. A deﬁnitive
prenatal diagnosis of amniotic ﬂuid test for trisomy 13 was
not carried out for any of the 16 patients. However, in 15
patients diagnosed with trisomy 13, some type of abnor-
mality was indicated in the ultrasonography test during the
course of pregnancy, such as intrauterine growth retardation
in11patientsandbrainmalformationsin5patients.Theterm
ofdeliveryrangedfrom33to40gestationalweeks(average:
35.9gestationalweeks).Regardingthemethodofdelivery,9
patients were delivered via a cesarean section and 7 patients
were delivered via a spontaneous cephalic delivery. The
deliverytermfortheperformanceofcesareansectionranged
from 33 to 40 gestational weeks (average: 35.8 gestational
weeks).
The average of Apgar Score at the time of birth was 4.25
points for 1 min scores and 6.5 points for 5 min scores. The
birth weight ranged from 1,582 to 3,378 g, with an average
weight of 2,243 g. The breakdown includes 7 patients
weighing 1,500 to 2,000 g, 5 patients weighing 2,000
to 2,500 g, 2 patients weighing 2,500 to 3,000 g, and
2 patients weighting at least 3,000 g.
Chromosomal Analysis, External Malformations,
and Organ Malformations (Table 2)
The chromosomal karyotypes of all 16 patients were diag-
nosed using a G-band method. The r karyotypes included
full trisomy 13 in 14 patients, mosaic type of trisomy 13 in
1patient,andRobertsoniantypeoftranslocationin1patient.
The major external craniofacial malformations included
scalpdefectsin5patientsfortheheadandcleftlipandpalate
in 10 patients for the face; malformation of abdomen inclu-
dedumbilicalherniain8patients.Polydactylywasnotedin6
patients for the extremities. Among the major organ
malformations,3patients had alobar and 1 patient had semi-
lobar type of holoprosencephaly. Dandy-Walker malfor-
mation was observed 1 patient and olfactory aplasia and
fenestration of the septum pellucidum in 1 patient for the
brain. As for the heart, some type of congenital cardiac dis-
order was observed in all patients. The breakdown includes
atrialseptaldefectin7patients,ventricularseptaldefectin6
patients, patentductusarteriosusin7patients, coarctationof
the aorta in 3 patients, endocardial cushion defect in 2
patients, tetralogy of Fallot (TOF) in 3 patients, and double-
outlet right ventricle (DORV) in 3 patients. Combined
respiratory malformations included congenital hypoplastic
lung in 2 cases and congenital tracheal stenosis in 2 cases.
Administration of Oxygen and the Use of Mechanical
Ventilation and Surgical Treatment (Table 3)
Signs of acute respiratory failure were observed in 13
patients after birth. To resuscitate, oxygen was adminis-
tered to all 16 patients. Mechanical ventilators were used
Table 1 Family history, age of parents, pregnancy, and delivery regarding 16 patients with trisomy 13
Patients Age of parents
(father/mother)
History of
previous
delivery
Gender Prenatal ultrasonographic
ﬁndings
Cesarean
section
Apgar score
(1 min/5 min)
Gestational
age (weeks)
Birth
weight
(g)
1 31/29 – M Hydrocephalus IUGR – 3/4 35 1,582
2 32/32 – F Holoprosencephaly
umbilical hernia severe
IUGR
? 1/2 35 1,756
3 32/31 – M IUGR ? 3/6 40 2,162
4 35/42 ? M Hydronephrosis ? 1/3 33 3,378
5 41/40 ? M IUGR oligoamnios ? 2/5 37 2,254
6 22/20 – F IUGR – 6/7 37 2,237
7 33/33 – F Hydrocephalus oligoamnios ? 8/9 35 2,540
8 30/35 ? M – – 8/9 36 2,380
9 34/32 – F Holoprosencephaly IUGR ? 1/3 36 2,784
10 22/21 – M IUGR – 8/8 37 2,342
11 36/35 – F Hydrocephalus IUGR
polydactyly origoamnios
– 4/9 35 1,960
12 29/33 – M Severe IUGR – 3/7 34 1,602
13 39/37 ? M Origoamnios
14 36/36 – F Severe IUGR – 8/10 37 1,746
15 47/34 ? M IUGR – 4/8 39 3,366
16 41/37 – M IUGR ? 3/6 35 1,950
M male, F female, IUGR intrauterine growth retardation
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123for 9 patients to control acute respiratory failure after tra-
cheal intubation. The tracheal intubation was unsuccessful
in 1 patient due to severe tracheal stenosis.
The various types of congenital malformations were
observedinall16patientswithtrisomy13;consultationswith
specialized surgeons were conducted to determine whether
surgical treatment would be possible. Due to the difﬁculty of
tube withdrawal after prolonged intubation, tracheotomy was
performed for 2 patients. After tracheotomy, respiratory
conditionsinbothpatients werestabilizedandtheywereable
to survive for long-time period over 7 years. Abdominal
operationfor umbilical herniawas performedin1patient and
for inguinal hernia in 1 patient. Plastic operation of the cleft
lip and palate was performed in 1 patient in order to improve
the cosmetic problem at 210 days of birth before discharge.
Cardiac surgery was performed in 2 patients with trisomy 13.
Ligation for patent ductus arteriosus and subclavian methods
for coarctation of the aorta were carried out for 1 patient but
she was died at 592 days of birth because of respiratory
failure.CardiacoperationusingBlalock–Taussigmethodwas
performed for TOF in 1 patient at 330 days of birth and she
has survived for more than 3 years and 3 months now.
Outcomes and Main Cause of Death (Table 4)
In-hospital death at NICU occurred in case of 9 patients,
whereas 7 patients were discharged with the condition of
homecare. Among them, 3 patients were referred by our
hospital to another specialized institution close to the
patients’ homes for training purpose of homecare nursing
at days 349, 251, and 63 after birth. The ages of 4 patients
discharged from our hospital to their homes while they
were alive were 336, 331, 256, and 204 days after birth.
The average of median hospital stay regarding 7 patients
who could be discharged including stay in another spe-
cialized institute was 256 days after birth. The survival
period of the16 patients with trisomy 13 ranged from death
at day 1 (within 24 h of birth) to 10 years and 1 month
(this patient lives until now).
The breakdown includes death at 1st day of birth, within
24 h, for 1 patient (6.25 %), death within 7 days of birth
for 4 patients (25.00 %), and death within 1 month of birth
for 7 patients (43.75 %). On the other hand, 9 patients
survived for more than 1 month (56.25 %), 6 patients
survived for more than 1 year (37.50 %), and 3
patients survived for more than 5 years (18.75 %). There-
fore, the survival rates at ages of 1 day, 1 week, 1 month,
6 months, 1 year, 3 years and 5 years were 93.75, 75.00,
56.25, 43.75, 37.50, 31.25, and 18.75 %, respectively.
Median survival time for all 16 patients, both males and
females, were 733, 887, and 534 days, respectively.
We also reviewed the data in detail to analyze the main
cause of death. Some characteristic trend was recognized as
follows: death occurred in 4 patients within 1 week of birth
Table 3 Administration of oxygen and the use of mechanical ventilation and surgical treatment, others with 16 patients of trisomy 13
Patients Resuscitation
of oxygen
Mechanical
ventilation
Mode of
ventilation
Surgical treatment Others
1 ? ––– –
2 ?? IMV – Seizures
3 ? ––– –
4 ?? IMV, HFO Operation for paracentesis of hydronephrosis –
5 ? ––– –
6 ? ––– –
7 ? ––– –
8 ?? IMV Operation for umbilical hernia
9 ?? IMV – Seizures
10 ? – – – HOT
11 ? – – Plastic operation for cleft lip and palate operation
for PDA ligation subcravian method for CoA
–
12 ?? IMV – Seizures
13 ?? IMV Blalock–Taussig operation for TOF –
14 ?? IMV – –
15 ?? IMV Tracheotomy operation for inguinal hernia operation
for buried penis
Seizures
16 ?? IMV Tracheotomy HOT
IMV intermittent mandatory ventilation, HFO high frequency oscillation, HOT home oxygen therapy, PDA patent ductus arteriosus, CoA
coarctation of the aorta, TOF tetralogy of Fallot
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123due to a major organ anomaly; especially, 3 patients had
DORV and in 2 of 3, intubation with ventilation manage-
ment was performed. On the other hand, 4 of 6 patients
from long-survival group (over 365 days, now living)
had some kind of surgery that included tracheotomy in
2 patients and cardiac surgery in other 2 patients. More-
over, 5 of 6 patients from long-survival group (over
365 days) had a history of ventilation therapy.
The longest survival time was set at 365 days (Fig. 1)
and 1,825 days equal 5 years (Fig. 2) in the Kaplan–Meier
survival curves prepared from the mortality data of all 16
patients with trisomy 13. These Kaplan–Meier survival
curves showed mainly two groups: one group that survived
for about 2 months and the other group survived for over
365 days.
Discussion
Among autosomal chromosomal abnormalities, birth is
generally believed to be possible in patients of trisomies
21, 18, and 13. Of these, trisomies 18 and 13 are also
referred to as fatal chromosomal abnormalities that lead to
the development of many severe malformations [14]. Most
patients with trisomy 18 and 13 present with severe
psychomotor delay, even if they survive for a long period
[4, 15, 16]. Historically since the 1980s, resuscitation and
surgical treatments for trisomy 18 and 13 have been dis-
cussed both from medical and ethical standpoints, taking
into consideration the quality of life for the patients and
families, medical and economical issues, and the medical
standards in different countries. In Japan, the concept of
‘‘no treatments beyond current treatments’’ as proposed by
Nishida and Sakamoto [12] of the Tokyo Women’s Med-
ical University has inﬂuenced many medical institutions
with regard to medical care and management of newborn
infants. However, recently, there are few reports of patients
with trisomy 13 in Japan who have survived for long
periods [17]. Notably, the current problem in Japan is, the
primary doctors who tend to patients with trisomy 13 or
trisomy 18 provide healthcare by their own medical
Table 4 Outcomes and life prognosis with 16 patients of trisomy 13
Patients Discharge(days) Transfer another
hospital (days)
Home care Survival time (days) Main cause of death
1 – – – 12 h Respiratory failure due to hypoplastic lung
2 – – – 1 DORV
3 – – – 1 DORV tracheal stenosis
4 – – – 2 DORV
5 – – – 11 Heart failure
6 – – – 14 PPHN respiratory failure
7 – – – 21 Heart failure respiratory failure
8 – – – 39 Heart failure
9 – – – 50 Heart failure respiratory failure
10 204 – ? 325 Bacterial infection
11 255 – ? 592 (live) –
12 63 63 ? 1186 Respiratory failure
13 349 349 ? 1219 (live) –
14 251 251 ? 1842 (live) –
15 336 – ? 2,705 s/o central apnea
16 331 – ? 3,713 (live) –
DORV double-outlet right ventricle, PPHN persistent pulmonary hypertension of newborn, s/o suspect of
Fig. 1 Kaplan–Meier survival curves. Kaplan–Meier survival curves
are shown for patients with trisomy 13 who received treatment at the
neonatal intensive care unit (NICU) of Dokkyo Medical University
Hospital. The data represent 16 trisomy 13 patients. The vertical and
horizontal axes represent % survival and survival time (days),
respectively, setting the longest survival time at 365 days
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123environments and policies, and no discrete guidelines in
this concern have been established. Regarding the medical
policy of negative intensive treatment performed without
the explanation of detailed medical information, a part of
support group members with trisomy 18 or trisomy 13 in
Japan have expressed a desire for more active intensive
treatment after informed consent.
As for the prognoses of trisomy 13, there is one known
report published in 2003 by the American Research Group
regarding a large-scale survey of 5,515 cases. According to
this report, the average age at the time of death was
10 days, but 5.6 % of the cases survived for more than
1 year [8]. Besides, other long-term survival cases were
reported including a 38-year-old adult case of trisomy 13
[18]. There have been several other reports about long-term
survivors with trisomy 13 [4, 5, 8, 16, 19]. As summarized
in Table 5, our data represent signiﬁcantly longer median
survival periods for the patients with trisomy 13 treated
intensively at the NICU.
Of note, two reports have compared between active
intensive treatment and non-active treatment with regard to
prognosis of trisomy 18 [11, 14] but no such reports are
available regarding trisomy 13. Herein, we present for the
ﬁrst time a study of patients with trisomy 13 who received
active intensive treatment and discuss the clinical picture
and prognosis. Our data suggest that the patients with tri-
somy 13 who have survived over 60 days after birth may
have a high probability of long-term survival. In the pre-
vious report on survival of trisomy 18 patients, those who
survived longer than 7 months after birth might have a high
probability of long-term survival prognosis [14]. In this
study, we should not only consider 9/16 (56.25 %) of
patients with trisomy 13 who died in the hospital without
discharge but also those 7/16 (43.75 %) of patients who
were discharged or transferred for purpose of homecare. As
our data reveal, one of the major causal factors involved in
long-term survival of patients with trisomy 13 is whether
the provision of active resuscitation should follow imme-
diately after birth, and then the various surgical treatments
should be performed in survivors such as tracheotomy and
cardiac surgery. Two previous studies reported intensive
cardiac management in patients with trisomy 13 or trisomy
18 [20, 21]. These studies summarized intensive cardiac
management including pharmacological intervention, per-
formed to improve the survival periods in patients with
trisomy 13 or trisomy 18. In our study, two patients
underwent cardiac surgery. One surgical procedure
involved ligation of patent ductus arteriosus and subclavian
methods for coarctation of the aorta, the other was Bla-
lock–Taussig procedure for TOF; and both survived for
long periods: 592 days and more than 3 years and
3 months (living until date), respectively. In addition, all 3
patients with DORV died within 2 days of birth, despite
that fact that ventilation management was performed in 2
cases.
Fig. 2 Kaplan–Meier survival curves. Kaplan–Meier survival curves
are shown for patients with trisomy 13 who received treatment at the
neonatal intensive care unit (NICU) of Dokkyo Medical University
Hospital. The data represent 16 trisomy 13 patients. The vertical and
horizontal axes represent % survival and survival time (days),
respectively, setting the longest survival time at 1,825 days
Table 5 Compared survival rates of trisomy 13 in our study with previously reported
Survival time (age) Denmark [4]
n = 76
% surviving
England [5]
n = 16
% surviving
Scotland [16]
n = 84
% surviving
Atlanta, USA [8]
n = 114
% surviving
Taiwan [19]
n = 28
% surviving
Japan (our study)
n = 16
% survival
1 day 77 69 75 86 89 93.75
7 days 40 38 50 56 61 75
1 month 23 13 28 30 29 56.25
6 months 10 0 ND 11 7 43.75
1 year ND 0 3 9 4 37.5
3 years ND 0 ND ND 4 31.25
5 years ND 0 ND ND ND 18.75
Median survival (days) 2.5 4 8.5 7 9 733
ND no data
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123In conclusion, although our clinical data represent a
small number of trisomy 13 patients, we did observe sig-
niﬁcantly better survival prognosis in the patients who
received intensive treatment management. Our clinical
results underscore the need to consider obtaining informed
consent and counseling from patients’ families for the
future determinations of treatment policy for trisomy 13
patients.
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